Zofran Lawsuit Plaintiffs Claim Fetal Exposure To Drug Caused Baby To Develop Atrial Septal Defect

March 31, 2016 – – ZofranLegal.com reports on a lawsuit which was filed in Louisiana against GlaxoSmithKline in reference to the anti-nausea drug they manufacture, Zofran. The plaintiffs filing the complaint are parents to a young boy, who allege that fetal exposure to Zofran through the mother caused their son to develop serious congenital heart defects. They claim that his specific defects are known as atrial septal defect and partial anomalous pulmonary venous return.

Partial anomalous pulmonary venous return is a rare congenital heart defect. It causes blood within the pulmonary vein to circulate improperly and return to the heart’s right atrium instead of the left atrium. Atrial septal defect happens when the heart wall (or septum) develops a hole generally separating its chambers and hindering the blood pumping process. The hole exposes oxygen rich blood to oxygen poor blood within the heart. A child born with both of these heart defects could have difficulty getting oxygenated blood and can often appear to have a bluish tinge to their skin, fingernails, or other areas of the body.

Court documents further detail that the boy’s mother claims to have been prescribed Zofran by her doctor during her first trimester of pregnancy as a morning sickness treatment. While the first trimester is a common time for expectant mothers to battle nausea and vomiting episodes, it is also a time when the fetus’ cells undergo rapid division and initial heart, mouth, and limb tissue formation occurs.

This mother is not alone in her claims. Across the nation, hundreds of other parents have filed lawsuits against GSK alleging that Zofran exposure caused their children to develop a range of birth defects. These plaintiff also commonly share a specific frustration: Zofran was never FDA-approved to treat pregnant women or tested for safety on this consumer group and their unborn babies. Despite this concerning and controversial fact, however, GSK marketed their drug “off-label” as a safe and effective treatment for morning sickness and also advertised it this way to Ob/Gyns and the general public, leading to mass “off-label” prescriptions.

As involved plaintiffs await what they are hoping to consider justice, the attorneys of Monheit Law are working to help other women who have used Zofran while pregnant and have later given birth to children with defects. Affected individuals may be entitled to significant compensation attained through legal action. To help these patients investigate their legal rights in full, Monheit Law is currently offering complimentary legal consultations for qualified parties.

To request additional Zofran birth defect lawsuit information, or to ask questions, please contact Michael Monheit, Esq., lead attorney of Monheit Law, by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60009002